WordPress WooCommerce Themes

Pharmacology: news from October 2025

1. FDA puts Intellia gene therapy on hold over an adverse reaction

In October, the FDA announced a clinical hold on two clinical trials by Intellia Therapeutics, a company working with CRISPR gene therapy. The reason was a serious rise in liver enzymes in one patient, which may indicate toxicity. 

  • This shows that even cutting-edge gene-editing technologies remain in a risk zone, and regulators are exercising more caution.
  • For the industry, it is a signal: the development of gene therapy must be accompanied by strict safety control.

2. Eli Lilly buys Adverum for ocular gene therapy

Eli Lilly agreed to acquire Adverum Biotechnologies for up to USD 261.7 million. 

  • The goal is to gain access to the gene therapy Ixo-vec for treating wet age-related macular degeneration (wAMD).
  • It is a potential “one-time” treatment (an injection) that could replace frequent injections of other drugs.
  • Analysts rate the market potential of Ixo-vec as very large, with possible sales in the billions of dollars.

3. Progress in gene therapy for rare diseases

  • Abeona Therapeutics: its gene therapy ABO-503 (an AAV vector) for the rare disease XLRS (X-linked retinoschisis) was selected by the FDA for the Rare Disease Endpoint Advancement (RDEA) pilot program. 
  • Regeneron reports updated data on its AAV version of the gene therapy DB-OTO, intended to treat hearing loss in children caused by an otoferlin mutation. 
  • Krystal Biotech received a “platform technology designation” from the FDA for its HSV vector for the gene therapy KB801 (neurotrophic keratitis). 
  • Tr1X: the FDA cleared the start of clinical trials of its therapy TRX319, a CAR-T cell (Tr1 Treg) therapy for progressive multiple sclerosis. 
  • BrainChild Bio signed an agreement with the CDMO OmniaBio to manufacture BCB-276 CAR-T cells for pediatric glioma.

4. Clinical news: oncology and innovative drugs

According to Targeted Oncology, in October 2025 the FDA approved or granted priority status to several therapies:

  • Lurbinectedin + atezolizumab received approval as maintenance therapy for metastatic small cell lung cancer. 
  • Orca-T, an allogeneic T-cell therapy, received priority review for hematologic malignancies such as acute myeloid leukemia. 
  • MT-125, a new small molecule, received Fast Track designation for the treatment of glioblastoma. 
  • The FDA also granted “breakthrough therapy” designation to zenocutuzumab (NRG1-positive cholangiocarcinoma) and Fast Track designation to the new ADC pamlectabart tismanitin for myeloma. 

5. Expanded indications for pediatric drugs

  • The FDA approved expanded indications for adalimumab-aaty (Yuflyma): it can now be used in adolescents (from 12 years) with hidradenitis suppurativa and in children from 2 years with non-infectious uveitis. 
  • Tezepelumab (Tezspire) from AstraZeneca and Amgen was approved as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps in patients from 12 years. 

⚠️ Risks and ethical questions

  • Gene therapy safety: as the Intellia hold shows, even very promising gene therapies can have serious side effects.
  • Price and access: the newest gene or cell treatments can be extremely expensive, which raises the question of how accessible they will be to the wider population.
  • Regulation: the rapid pace of technology requires clear regulatory rules to balance innovation with patient safety.

📌 Conclusions

  • October 2025 showed that investment in gene and cell therapies is growing: big pharma companies are striking deals, and clinical trials are reaching a new level.
  • However, regulators pose serious challenges: safety and efficacy are at the center of attention.
  • At the same time, innovative oncology is developing, with new combinations and cell-based approaches.
  • Expanding drug indications for children is a positive trend, allowing modern medicines to be used in wider age groups.

Useful links

Add comment

Your email address will not be published. Required fields are marked

Don't forget to share